drugset / Trial / NCT00422461

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

NCT00422461

Phase 2 Completed 135 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure

Timeline

Start
2007-02-27
Primary completion
2008-01-28
Completion
2008-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00489791 Small molecule 4 mg Oral
Subject PF-00489791 Small molecule 10 mg Oral
Subject PF-00489791 Small molecule 40 mg Oral